MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled ... This press release contains forward-looking statements about the planned release of results from an ongoing clinical study that ... Read More

Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole

today announced topline results from the OPERA-S study: a Phase 2 safety and tolerability study in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against ... Read More

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease Designation ... About the Phase 2/3 AMPLITUDE Study Inaxaplin is a potential first-in-class ... Read More

INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

“It is exciting to share data from this study’s standardized meal challenge, demonstrating inhaled insulin can help address this unmet need.” The 17-week endpoint ... Read More

Press Release Portal

Does your organization or business have an announcement to promote? The Marietta Daily Journal's self-service Press Release Portal can get your organization's announcement the placement it needs. Read More

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

The Phase 1 study is expected to commence in the U.K in December 2023. "Receiving regulatory clearance from U.K.'s MHRA for our inhaled mRNA ... underlying respiratory disease e.g., asthma or ... Read More

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care. Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and Teaching Chair at the ... Read More

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

"The kidney community is strongly encouraged by inaxaplin’s potential ... Phase 3 portion of the study. The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease ... Read More

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care. Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and ... after the date of this ... Read More

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

Christine Benz’s Portfolios Best Companies to Own Best ETFs Guide to 529 Plans Asset Management Companies Topics Portfolio Construction Economy Sustainable Investing Personal Finance ... Read More